NEW YORK, November 5, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting HCA Holdings Inc (NYSE: HCA),
Walgreen Company (NYSE: WAG), Allergan, Inc. (NYSE: AGN), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEG), and AmerisourceBergen Corp. (NYSE: ABC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
HCA Holdings Inc. Research Report
On October 30, 2013, HCA Holdings Inc., (HCA) announced that 110 of its licensed hospitals in the U.S. are included among The Joint Commission's new 2013 list of Top Performers on Key Quality Measures. "This distinction by The Joint Commission is significant because the measures they use to determine Top Performers are based on scientific evidence about practices that lead to better patient outcomes," said Dr. Jonathan B. Perlin, HCA's Chief Medical Officer and President of the Company's Clinical and Physician Services Group. "We are pleased that 80 percent of our hospitals have been recognized for their clinical excellence and are listed among the top U.S. hospitals." The Full Research Report on HCA Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/be59_HCA]
Walgreen Company Research Report
On October 30, 2013, the Walgreen Company (Walgreens) and the Accreditation Association for Ambulatory Health Care (AAAHC) announced that Healthcare Clinics at select Walgreens stores nationwide have received accreditation from AAAHC. According to the Company, the accreditation distinguishes Healthcare Clinics at select Walgreens as delivering high-quality care in an environment that promotes patient safety. "AAAHC shares our focus on high-quality, affordable and coordinated patient care, and the accreditation is another important step in Walgreens evolution from traditional retail drugstore to a community health care destination," said Heather Helle, Divisional Vice President, Walgreens Consumer Solutions Group. "The AAAHC accreditation process requires a rigorous and complex series of evaluations, and we're proud to be recognized for delivering the highest levels of comprehensive, quality care to our patients in order to help them get, stay and live well." The Full Research Report on Walgreen Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/844c_WAG]
Allergan, Inc Research Report
On October 30, 2013, Allergan, Inc. (Allergan) released its Q3 2013 operating results. The Company's total product net sales stood at $1.5 billion, up 12.9% YoY. Net diluted EPS attributable to its stockholders came in at $1.00 for the quarter, compared to $0.82 in Q3 2012. The Company stated that it expects total product net sales for Q4 2013 to be between $1,585 million and $1,660 million (which excludes the obesity intervention business); and between $6,125 million and $6,200 million for full-year 2013. Further, Allergan's Board of Directors declared a Q3 2013 dividend of $0.05 per share, payable on December 11, 2013 to stockholders of record as of November 20, 2013. The Full Research Report on Allergan, Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/182a_AGN]
Aegerion Pharmaceuticals, Inc. Research Report
On October 30, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced its Q3 2013 and 9M 2013 financial results. Net loss for Q3 2013 was $12.5 million, or $0.43 per share, compared with a net loss of $14.9 million, or $0.59 per share, for Q3 2012. For 9M 2013, net loss was $49.5 million, or $1.72 per share, compared with a net loss of $40.5 million, or $1.76 per share, in 9M 2012. Further, Aegerion raised its full year 2013 revenue guidance for net product sales to $45 million to $50 million range, from the previous range of $30 million to $35 million. The Company stated that this upward revision primarily reflects Aegerion's results and insights to date with respect to the launch of JUXTAPID in the U.S. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ffc5_AEG]
AmerisourceBergen Corp. Research Report
On October 30, 2013, AmerisourceBergen Corp. (AmerisourceBergen) stocks fell 0.88%, closing at $65.22 per share. Over the previous three trading sessions, shares of AmerisourceBergen declined 0.03% compared to the Dow Jones which gained 0.31% during the same period. The Full Research Report on AmerisourceBergen Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/29fb_ABC]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner